Skip to main content

Table 4 Prediction of CS-PCa (as determined by GS) by individual markers, clinical variables, and ProCUrE

From: A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer

A

Univariable

1st quartile

3rd quartile

Difference

OR

95% CI.

p value

 ProCUrE

− 2.0006

− 1.0828

0.91789

1.58***

1.28

1.96

< 0.0001

 APC

0

0.37652

0.37652

1.24***

1.10

1.39

0.0003

 HOXD3

0.43965

5.2043

4.7646

1.54***

1.24

1.90

< 0.0001

 GSTP1

0

0.1216

0.1216

1.06**

1.02

1.10

0.0013

 KLK10

0

0.12665

0.12665

1.07**

1.02

1.11

0.0048

 TGFβ2

0

0.309

0.309

1.03*

1.00

1.06

0.0481

 TBX15

0

0.21295

0.21295

1.16***

1.08

1.24

< 0.0001

 PSA

4.565

10.48

5.915

1.98***

1.46

2.68

< 0.0001

 Age

59

71

12

1.66**

1.13

2.45

0.0105

 PSA density

0.09

0.2

0.11

2.35***

1.51

3.68

0.0002

 Prostate volume

40

70

30

0.70

0.47

1.06

0.0926

B

Multivariable

OR

95% CI.

p value

 ProCUrE

1.358*

1.051

1.754

0.0194

 PSA

0.816

0.373

1.785

0.6108

 Age

2.718**

1.295

5.707

0.0082

 PSA density

2.878**

1.455

5.694

0.0024

  1. Using univariable and multivariable logistic regression, the ability of individual methylation markers, ProCUrE, and clinical variables to differentiate CI-PCa and CS-PCa as determined by GS was assessed in the training cohort. Since the scale of each variable is different, interquartile range odds ratios were estimated (logistic regression model *p < 0.05, **p < 0.01, ***p < 0.001)